How to Obtain a Letter from FDA Stating that Bioequivalence Study Protocols Contain Safety Protections Comparable to Applicable REMS for RLD

Docket Number:: FDA-2014-D-1891
Issued by:: Guidance Issuing Office

Center for Drug Evaluation and Research

This guidance describes how a prospective abbreviated new drug application (ANDA) applicant 19 may request a letter stating that FDA has determined: (1) that the prospective applicant’s 20 bioequivalence (BE) study protocol contains safety protections comparable to those in the risk 21 evaluation and mitigation strategy (REMS) with elements to assure safe use (ETASU) applicable 22 to the reference listed drug (RLD), and (2) that FDA will not consider it a violation of the REMS 23 for the RLD sponsor to provide a sufficient quantity of the RLD to the interested generic firm or 24 its agent to allow the firm to perform the testing necessary to support its ANDA.

Submit Comments

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2014-D-1891.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

You just read:

How to Obtain a Letter from FDA Stating that Bioequivalence Study Protocols Contain Safety Protections Comparable to Applicable REMS for RLD

Distribution channels: Healthcare & Pharmaceuticals Industry

EIN Presswire's priority is author transparency. We do our best to weed out false and misleading content. The content above is the sole responsibility of the author who makes it available. If you have any complaints, kindly contact the author above.